China Pharma Holdings (CPHI) Income towards Parent Company (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly Income towards Parent Company came in at -$1.1 million in Q1 2026, down 45.52% YoY from -$2.1 million in Q1 2025, and up 6.46% on a QoQ basis from -$1.2 million in Q4 2025.
China Pharma Holdings (CPHI) Income towards Parent Company (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 17 years of Income towards Parent Company data on file, last reported at -$1.1 million in Q1 2026.
- Quarterly Income towards Parent Company fell 45.52% year-over-year to -$1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.5 million (up 22.36% YoY) and the FY2025 annual result came in at -$2.4 million, up 32.7% from the prior year.
- Income towards Parent Company advanced to -$1.1 million in Q1 2026, from -$1.2 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$475976.0 in Q1 2023 to a low of -$1.4 million in Q2 2024.
- A 5-year average of -$948160.5 and a median of -$955892.0 in 2024 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2024 — Income towards Parent Company plunged 142.51% — and 2025, when it jumped 63.26%.
- Tracing CPHI's Income towards Parent Company over 5 years: stood at -$1.3 million in 2022, then climbed by 2.53% to -$1.2 million in 2023, then increased by 0.63% to -$1.2 million in 2024, then grew by 0.19% to -$1.2 million in 2025, then gained by 6.46% to -$1.1 million in 2026.
- The last three Income towards Parent Company figures came in at -$1.1 million (Q1 2026), -$1.2 million (Q4 2025), and -$651482.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | China Pharma Holdings | 41.94 Mn | 41.64 Mn | 83,566.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.14 Mn |
| Dec 31, 2025 | -1.22 Mn |
| Sep 30, 2025 | -651,482.00 |
| Jun 30, 2025 | -528,367.00 |
| Mar 31, 2025 | -785,572.00 |
| Dec 31, 2024 | -1.22 Mn |
| Sep 30, 2024 | -1.12 Mn |
| Jun 30, 2024 | -1.44 Mn |
| Mar 31, 2024 | -955,892.00 |
| Dec 31, 2023 | -1.23 Mn |
| Sep 30, 2023 | -777,600.00 |
| Jun 30, 2023 | -593,029.00 |
| Mar 31, 2023 | -475,976.00 |
| Dec 31, 2022 | -1.26 Mn |
| Sep 30, 2022 | -790,773.00 |
| Jun 30, 2022 | -888,394.00 |
| Mar 31, 2022 | -1.03 Mn |
| Dec 31, 2021 | -980,719.00 |
| Sep 30, 2021 | -826,669.00 |
| Jun 30, 2021 | -824,761.00 |